Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study
Abstract Background Limited research has been conducted on whether advances in novel biologics and biosimilars have improved the treatment journey preceding biologics. Objectives To map the overall treatment journey preceding the initiation of first biologic therapy in patients with psoriasis (PsO)...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.194 |
| _version_ | 1797435250506203136 |
|---|---|
| author | David Thein Nana A. L. Rosenø Mia‐Louise Nielsen Lars Erik Kristensen Julia‐Tatjana Maul Jashin J. Wu Simon Francis Thomsen Jacob P. Thyssen Alexander Egeberg |
| author_facet | David Thein Nana A. L. Rosenø Mia‐Louise Nielsen Lars Erik Kristensen Julia‐Tatjana Maul Jashin J. Wu Simon Francis Thomsen Jacob P. Thyssen Alexander Egeberg |
| author_sort | David Thein |
| collection | DOAJ |
| description | Abstract Background Limited research has been conducted on whether advances in novel biologics and biosimilars have improved the treatment journey preceding biologics. Objectives To map the overall treatment journey preceding the initiation of first biologic therapy in patients with psoriasis (PsO) and psoriatic arthritis (PsA), as well as the changes over time. Methods Using Danish nationwide registries, we included all patients treated with a first‐time biologic (2010–2018) for either PsO or PsA and reported the medical treatment journey. We used Sankey diagrams to illustrate the flow of treatment series. Results The study included 2082 patients with PsO (62.5% male) and 1831 patients with PsA (42.3% male). Before biologics, 49.5% treated for PsO and 36.8% treated for PsA received ≥2 type therapies and 59.3% with PsO and 25.5% with PsA received ≥3 treatment series. Median time from first systemic therapy to a biologic was 3.9 years (Q1–Q3, 1.3–4.1) for PsO and 2.1 years (Q1–Q3, 0.6–5.8) for PsA. The majority of patients with PsO (1174 [56.4%]) received multiple treatment series with the same drug, while almost a third of patients with PsA (572 [31.2%]) did the same. Twelve percent of patients with PsO and 6.4% of patients with PsA repeated treatment with a drug they had already stopped for an alternative treatment. Conclusions Although most patients are adequately managed, our findings suggest the possibility of a yet too long and complicated treatment journey before starting biologics. |
| first_indexed | 2024-03-09T10:45:28Z |
| format | Article |
| id | doaj.art-6abf915d987d47869945d2dafe4986f2 |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-03-09T10:45:28Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-6abf915d987d47869945d2dafe4986f22023-12-01T10:43:27ZengWileyJEADV Clinical Practice2768-65662023-12-012485786310.1002/jvc2.194Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization studyDavid Thein0Nana A. L. Rosenø1Mia‐Louise Nielsen2Lars Erik Kristensen3Julia‐Tatjana Maul4Jashin J. Wu5Simon Francis Thomsen6Jacob P. Thyssen7Alexander Egeberg8Department of Dermatology, Bispebjerg Hospital University of Copenhagen Copenhagen DenmarkDepartment of Dermatology, Bispebjerg Hospital University of Copenhagen Copenhagen DenmarkDepartment of Dermatology, Bispebjerg Hospital University of Copenhagen Copenhagen DenmarkThe Parker Institute, Bispebjerg and Frederiksberg Hospital University of Copenhagen Copenhagen DenmarkDepartment of Dermatology University of Zürich Zürich SwitzerlandDepartment of Dermatology University of Miami Miller School of Medicine Miami Florida USADepartment of Dermatology, Bispebjerg Hospital University of Copenhagen Copenhagen DenmarkDepartment of Dermatology, Bispebjerg Hospital University of Copenhagen Copenhagen DenmarkDepartment of Dermatology, Bispebjerg Hospital University of Copenhagen Copenhagen DenmarkAbstract Background Limited research has been conducted on whether advances in novel biologics and biosimilars have improved the treatment journey preceding biologics. Objectives To map the overall treatment journey preceding the initiation of first biologic therapy in patients with psoriasis (PsO) and psoriatic arthritis (PsA), as well as the changes over time. Methods Using Danish nationwide registries, we included all patients treated with a first‐time biologic (2010–2018) for either PsO or PsA and reported the medical treatment journey. We used Sankey diagrams to illustrate the flow of treatment series. Results The study included 2082 patients with PsO (62.5% male) and 1831 patients with PsA (42.3% male). Before biologics, 49.5% treated for PsO and 36.8% treated for PsA received ≥2 type therapies and 59.3% with PsO and 25.5% with PsA received ≥3 treatment series. Median time from first systemic therapy to a biologic was 3.9 years (Q1–Q3, 1.3–4.1) for PsO and 2.1 years (Q1–Q3, 0.6–5.8) for PsA. The majority of patients with PsO (1174 [56.4%]) received multiple treatment series with the same drug, while almost a third of patients with PsA (572 [31.2%]) did the same. Twelve percent of patients with PsO and 6.4% of patients with PsA repeated treatment with a drug they had already stopped for an alternative treatment. Conclusions Although most patients are adequately managed, our findings suggest the possibility of a yet too long and complicated treatment journey before starting biologics.https://doi.org/10.1002/jvc2.194acitretinazathioprinebiologicscyclosporinedimethylfumaratehydroxychloroquine |
| spellingShingle | David Thein Nana A. L. Rosenø Mia‐Louise Nielsen Lars Erik Kristensen Julia‐Tatjana Maul Jashin J. Wu Simon Francis Thomsen Jacob P. Thyssen Alexander Egeberg Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study JEADV Clinical Practice acitretin azathioprine biologics cyclosporine dimethylfumarate hydroxychloroquine |
| title | Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study |
| title_full | Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study |
| title_fullStr | Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study |
| title_full_unstemmed | Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study |
| title_short | Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study |
| title_sort | mapping the road to biologics in psoriasis and psoriatic arthritis a nationwide drug utilization study |
| topic | acitretin azathioprine biologics cyclosporine dimethylfumarate hydroxychloroquine |
| url | https://doi.org/10.1002/jvc2.194 |
| work_keys_str_mv | AT davidthein mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy AT nanaalrosenø mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy AT mialouisenielsen mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy AT larserikkristensen mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy AT juliatatjanamaul mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy AT jashinjwu mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy AT simonfrancisthomsen mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy AT jacobpthyssen mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy AT alexanderegeberg mappingtheroadtobiologicsinpsoriasisandpsoriaticarthritisanationwidedrugutilizationstudy |